{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:29:13Z","timestamp":1786663753233,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203673"],"award-info":[{"award-number":["82203673"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515013180"],"award-info":[{"award-number":["2024A1515013180"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Urothelial bladder cancer (UBC) poses a considerable threat to public health, and its clinical management is limited by high recurrence rates and a tendency for progression. While dysregulation of the ubiquitin\u2012proteasome system (UPS) is a hallmark of tumorigenesis, the specific landscape of deubiquitinating enzymes (DUBs) in UBC remains largely underexplored. Multiple transcriptomic datasets were used for a comprehensive screening of ubiquitination-related genes in UBC, and ZRANB1 was identified as a potential oncogenic DUB, whose expression was validated using immunohistochemistry. High ZRANB1 expression was correlated with advanced pathological T stage, lymph node metastasis, and poor overall survival. The oncogenic role of ZRANB1 was assessed by proliferation, migration, and invasion assays in vitro, as well as in subcutaneous xenograft and lymph node metastasis models in vivo. Using immunoprecipitation coupled with mass spectrometry, we revealed that ZRNAB1 acted as a DUB to prevent the UPS-dependent degradation of SF3B3. The ZRANB1-SF3B3 axis subsequently modulates the alternative splicing of the cell cycle checkpoint kinase CHEK2, specifically inhibiting the production of the exon 4-skipped isoform (CHEK2-e4-). We demonstrated that while full-length CHEK2 is permissive for growth, the CHEK2-e4- isoform exerts a potent tumour-suppressive effect. This study reveals a novel post-translational mechanism linking the UPS to the RNA splicing machinery in UBC. ZRANB1 promotes tumorigenesis by stabilizing SF3B3 to prevent the generation of the tumour-suppressive CHEK2-e4- isoform, suggesting that ZRANB1 is a promising prognostic biomarker and therapeutic target.<\/jats:p>","DOI":"10.1038\/s41419-026-08964-y","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:13:39Z","timestamp":1781003619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ZRANB1 promotes cell proliferation and lymph node metastasis through SF3B3-mediated alternative splicing of CHEK2 in urothelial bladder cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5289-308X","authenticated-orcid":false,"given":"Dong","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5247-1596","authenticated-orcid":false,"given":"Qingqing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0335-706X","authenticated-orcid":false,"given":"Dejuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3517-4110","authenticated-orcid":false,"given":"Jianguang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"8964_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8964_CR2","doi-asserted-by":"publisher","first-page":"8916","DOI":"10.1097\/JS9.0000000000003254","volume":"111","author":"H Li","year":"2025","unstructured":"Li H, Zeng S, Yang C, Yang Y, Cao Z, Hu Z, et al. Global, regional, and national burden and trends of bladder cancer in individuals aged 55 years and older from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Int J Surg. 2025;111:8916\u201333.","journal-title":"Int J Surg"},{"key":"8964_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19199-z","volume":"8","author":"MCS Wong","year":"2018","unstructured":"Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018;8:1129.","journal-title":"Sci Rep"},{"key":"8964_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1170124","volume":"13","author":"K Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne K, Henne C, Mariappan P, Geiges G, Pohlmann J, Pollock RF. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124.","journal-title":"Front Oncol"},{"key":"8964_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/bmjgh-2020-004128","volume":"6","author":"S Safiri","year":"2021","unstructured":"Safiri S, Kolahi AA, Naghavi M. Global Burden of Disease Bladder Cancer C. Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease study 2019. BMJ Glob Health. 2021;6:11.","journal-title":"BMJ Glob Health"},{"key":"8964_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.eururo.2020.09.006","volume":"78","author":"JY Teoh","year":"2020","unstructured":"Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol. 2020;78:893\u2013906.","journal-title":"Eur Urol"},{"key":"8964_CR7","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/BF03262330","volume":"21","author":"MF Botteman","year":"2003","unstructured":"Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315\u201330.","journal-title":"Pharmacoeconomics"},{"key":"8964_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25\u201341.","journal-title":"Nat Rev Cancer"},{"key":"8964_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carrion A, Cathomas R, Comperat E, Efstathiou JA, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol. 2024;85:17\u201331.","journal-title":"Eur Urol"},{"key":"8964_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425\u201379.","journal-title":"Annu Rev Biochem"},{"key":"8964_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/cdd.2012.72","volume":"20","author":"S Shaid","year":"2013","unstructured":"Shaid S, Brandts CH, Serve H, Dikic I. Ubiquitination and selective autophagy. Cell Death Differ. 2013;20:21\u201330.","journal-title":"Cell Death Differ"},{"key":"8964_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06183-3","volume":"14","author":"L Gao","year":"2023","unstructured":"Gao L, Zhang W, Shi XH, Chang X, Han Y, Liu C, et al. The mechanism of linear ubiquitination in regulating cell death and correlative diseases. Cell Death Dis. 2023;14:659.","journal-title":"Cell Death Dis"},{"key":"8964_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1146\/annurev-biochem-061516-044916","volume":"86","author":"TET Mevissen","year":"2017","unstructured":"Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem. 2017;86:159\u201392.","journal-title":"Annu Rev Biochem"},{"key":"8964_CR14","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.7150\/ijbs.69411","volume":"18","author":"S Han","year":"2022","unstructured":"Han S, Wang R, Zhang Y, Li X, Gan Y, Gao F, et al. The role of ubiquitination and deubiquitination in tumor invasion and metastasis. Int J Biol Sci. 2022;18:2292\u2013303.","journal-title":"Int J Biol Sci"},{"key":"8964_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S1357-2725(02)00390-4","volume":"35","author":"M Groll","year":"2003","unstructured":"Groll M, Huber R. Substrate access and processing by the 20S proteasome core particle. Int J Biochem Cell Biol. 2003;35:606\u201316.","journal-title":"Int J Biochem Cell Biol"},{"key":"8964_CR16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrm2245","volume":"8","author":"DJ Klionsky","year":"2007","unstructured":"Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol. 2007;8:931\u20137.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8964_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev.pharmtox.051208.165340","volume":"49","author":"AL Schwartz","year":"2009","unstructured":"Schwartz AL, Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharm Toxicol. 2009;49:73\u201396.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"8964_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molmed.2023.05.006","volume":"29","author":"D Han","year":"2023","unstructured":"Han D, Wang L, Jiang S, Yang Q. The ubiquitin-proteasome system in breast cancer. Trends Mol Med. 2023;29:599\u2013621.","journal-title":"Trends Mol Med"},{"key":"8964_CR19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842\u201362.","journal-title":"Nat Rev Cancer"},{"key":"8964_CR20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/cr.2016.31","volume":"26","author":"X Huang","year":"2016","unstructured":"Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 2016;26:484\u201398.","journal-title":"Cell Res"},{"key":"8964_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nsmb.2169","volume":"19","author":"JD Licchesi","year":"2011","unstructured":"Licchesi JD, Mieszczanek J, Mevissen TE, Rutherford TJ, Akutsu M, Virdee S, et al. An ankyrin-repeat ubiquitin-binding domain determines TRABID\u2019s specificity for atypical ubiquitin chains. Nat Struct Mol Biol. 2011;19:62\u201371.","journal-title":"Nat Struct Mol Biol"},{"key":"8964_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110200","volume":"90","author":"D Miao","year":"2022","unstructured":"Miao D, Wang Y, Jia Y, Tong J, Jiang S, Liu L. ZRANB1 enhances stem-cell-like features and accelerates tumor progression by regulating Sox9-mediated USP22\/Wnt\/beta-catenin pathway in colorectal cancer. Cell Signal. 2022;90:110200.","journal-title":"Cell Signal"},{"key":"8964_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06836-x","volume":"15","author":"R Yan","year":"2024","unstructured":"Yan R, Liu D, Guo H, Liu M, Lv D, Bjorkblom B, et al. LAPTM4B counteracts ferroptosis via suppressing the ubiquitin-proteasome degradation of SLC7A11 in non-small cell lung cancer. Cell Death Dis. 2024;15:436.","journal-title":"Cell Death Dis"},{"key":"8964_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06000-x","volume":"14","author":"D Yan","year":"2023","unstructured":"Yan D, He Q, Pei L, Yang M, Huang L, Kong J, et al. The APC\/C E3 ligase subunit ANAPC11 mediates FOXO3 protein degradation to promote cell proliferation and lymph node metastasis in urothelial bladder cancer. Cell Death Dis. 2023;14:516.","journal-title":"Cell Death Dis"},{"key":"8964_CR25","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s13402-023-00826-5","volume":"46","author":"L Pei","year":"2023","unstructured":"Pei L, Yan D, He Q, Kong J, Yang M, Ruan H, et al. LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder. Cell Oncol (Dordr). 2023;46:1509\u201327.","journal-title":"Cell Oncol (Dordr)"},{"key":"8964_CR26","doi-asserted-by":"publisher","first-page":"11314","DOI":"10.18632\/aging.102530","volume":"11","author":"Q He","year":"2019","unstructured":"He Q, Huang L, Yan D, Bi J, Yang M, Huang J, et al. CircPTPRA acts as a tumor suppressor in bladder cancer by sponging miR-636 and upregulating KLF9. Aging (Albany NY). 2019;11:11314\u201328.","journal-title":"Aging (Albany NY)"},{"key":"8964_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1083\/jcb.202212072","volume":"222","author":"S Huang","year":"2023","unstructured":"Huang S, Zhang Q, Zhao M, Wang X, Zhang Y, Gan B, et al. The deubiquitinase ZRANB1 is an E3 ubiquitin ligase for SLC7A11 and regulates ferroptotic resistance. J Cell Biol. 2023;222:11.","journal-title":"J Cell Biol"},{"key":"8964_CR28","first-page":"4807","volume":"11","author":"Q Li","year":"2021","unstructured":"Li Q, Chao Q, Liu Y, Fang J, Xie J, Zhen J, et al. Deubiquitinase ZRANB1 drives hepatocellular carcinoma progression through SP1-LOXL2 axis. Am J Cancer Res. 2021;11:4807\u201325.","journal-title":"Am J Cancer Res"},{"key":"8964_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-024-03053-4","volume":"43","author":"T Xu","year":"2024","unstructured":"Xu T, Li X, Zhao W, Wang X, Jin L, Feng Z, et al. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis. J Exp Clin Cancer Res. 2024;43:126.","journal-title":"J Exp Clin Cancer Res"},{"key":"8964_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215711","volume":"538","author":"Y Qiao","year":"2022","unstructured":"Qiao Y, Shi Q, Yuan X, Ding J, Li X, Shen M, et al. RNA binding protein RALY activates the cholesterol synthesis pathway through an MTA1 splicing switch in hepatocellular carcinoma. Cancer Lett. 2022;538:215711.","journal-title":"Cancer Lett"},{"key":"8964_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cells9122675","volume":"9","author":"L Stolarova","year":"2020","unstructured":"Stolarova L, Kleiblova P, Janatova M, Soukupova J, Zemankova P, Macurek L, et al. CHEK2 germline variants in cancer predisposition: stalemate rather than checkmate. Cells. 2020;9:12.","journal-title":"Cells"},{"key":"8964_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38784-z","volume":"14","author":"YH Chen","year":"2023","unstructured":"Chen YH, Chen HH, Wang WJ, Chen HY, Huang WS, Kao CH, et al. TRABID inhibition activates cGAS\/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation. Nat Commun. 2023;14:3050.","journal-title":"Nat Commun"},{"key":"8964_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","volume":"6","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Qian J, Gu C, Yang Y. Alternative splicing and cancer: a systematic review. Signal Transduct Target Ther. 2021;6:78.","journal-title":"Signal Transduct Target Ther"},{"key":"8964_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature08909","volume":"463","author":"TW Nilsen","year":"2010","unstructured":"Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010;463:457\u201363.","journal-title":"Nature"},{"key":"8964_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","volume":"17","author":"SC Bonnal","year":"2020","unstructured":"Bonnal SC, Lopez-Oreja I, Valcarcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17:457\u201374.","journal-title":"Nat Rev Clin Oncol"},{"key":"8964_CR36","doi-asserted-by":"crossref","unstructured":"Piovesan A, Caracausi M, Antonaros F, Pelleri MC, Vitale L. GeneBase 1.1: a tool to summarize data from NCBI gene datasets and its application to an update of human gene statistics. Database (Oxford). 2016;2016:1\u221213.","DOI":"10.1093\/database\/baw153"},{"key":"8964_CR37","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1261\/rna.075135.120","volume":"26","author":"H Shenasa","year":"2020","unstructured":"Shenasa H, Movassat M, Forouzmand E, Hertel KJ. Allosteric regulation of U1 snRNP by splicing regulatory proteins controls spliceosomal assembly. RNA. 2020;26:1389\u201399.","journal-title":"RNA"},{"key":"8964_CR38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrg2776","volume":"11","author":"H Keren","year":"2010","unstructured":"Keren H, Lev-Maor G, Ast G. Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet. 2010;11:345\u201355.","journal-title":"Nat Rev Genet"},{"key":"8964_CR39","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.cmet.2013.04.013","volume":"17","author":"I Babic","year":"2013","unstructured":"Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013;17:1000\u20138.","journal-title":"Cell Metab"},{"key":"8964_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nsmb.2207","volume":"19","author":"O Anczukow","year":"2012","unstructured":"Anczukow O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012;19:220\u20138.","journal-title":"Nat Struct Mol Biol"},{"key":"8964_CR41","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1038\/s41388-017-0119-6","volume":"37","author":"F Liu","year":"2018","unstructured":"Liu F, Dai M, Xu Q, Zhu X, Zhou Y, Jiang S, et al. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-kappaB-CD47 axis. Oncogene. 2018;37:2394\u2013409.","journal-title":"Oncogene"},{"key":"8964_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ebiom.2018.11.007","volume":"38","author":"J Sheng","year":"2018","unstructured":"Sheng J, Zhao Q, Zhao J, Zhang W, Sun Y, Qin P, et al. SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistance. EBioMedicine. 2018;38:113\u201326.","journal-title":"EBioMedicine"},{"key":"8964_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000338941","volume":"35","author":"J Liu","year":"2012","unstructured":"Liu J, Huang B, Xiao Y, Xiong HM, Li J, Feng DQ, et al. Aberrant expression of splicing factors in newly diagnosed acute myeloid leukemia. Onkologie. 2012;35:335\u201340.","journal-title":"Onkologie"},{"key":"8964_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj4009","volume":"10","author":"L Deng","year":"2024","unstructured":"Deng L, Liao L, Zhang YL, Yang SY, Hu SY, Andriani L, et al. SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1. Sci Adv. 2024;10:eadj4009.","journal-title":"Sci Adv"},{"key":"8964_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01939-7","volume":"23","author":"Z Bian","year":"2024","unstructured":"Bian Z, Yang F, Xu P, Gao G, Yang C, Cao Y, et al. LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM. Mol Cancer. 2024;23:23.","journal-title":"Mol Cancer"},{"key":"8964_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405997","volume":"11","author":"H He","year":"2024","unstructured":"He H, Zhou Q, Zhang Y, Li Y, Ding L, Shen T, et al. PTBP1 regulates DNMT3B alternative splicing by interacting with RALY to enhance the radioresistance of prostate cancer. Adv Sci (Weinh). 2024;11:e2405997.","journal-title":"Adv Sci (Weinh)"},{"key":"8964_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100728","volume":"53","author":"R Sciarrillo","year":"2020","unstructured":"Sciarrillo R, Wojtuszkiewicz A, Assaraf YG, Jansen G, Kaspers GJL, Giovannetti E, et al. The role of alternative splicing in cancer: from oncogenesis to drug resistance. Drug Resist Updat. 2020;53:100728.","journal-title":"Drug Resist Updat"},{"key":"8964_CR48","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00439-017-1792-9","volume":"136","author":"J Munkley","year":"2017","unstructured":"Munkley J, Livermore K, Rajan P, Elliott DJ. RNA splicing and splicing regulator changes in prostate cancer pathology. Hum Genet. 2017;136:1143\u201354.","journal-title":"Hum Genet"},{"key":"8964_CR49","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-018-0085-0","volume":"15","author":"A Paschalis","year":"2018","unstructured":"Paschalis A, Sharp A, Welti JC, Neeb A, Raj GV, Luo J, et al. Alternative splicing in prostate cancer. Nat Rev Clin Oncol. 2018;15:663\u201375.","journal-title":"Nat Rev Clin Oncol"},{"key":"8964_CR50","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley RK, Anczukow O. RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer. 2023;23:135\u201355.","journal-title":"Nat Rev Cancer"},{"key":"8964_CR51","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","volume":"36","author":"J Paik","year":"2022","unstructured":"Paik J. Risdiplam: a review in spinal muscular atrophy. CNS Drugs. 2022;36:401\u201310.","journal-title":"CNS Drugs"},{"key":"8964_CR52","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1126\/science.1084155","volume":"300","author":"MM Golas","year":"2003","unstructured":"Golas MM, Sander B, Will CL, Luhrmann R, Stark H. Molecular architecture of the multiprotein splicing factor SF3b. Science. 2003;300:980\u20134.","journal-title":"Science"},{"key":"8964_CR53","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1093\/nar\/gkae185","volume":"52","author":"H Li","year":"2024","unstructured":"Li H, Ding Z, Fang ZY, Long N, Ang HY, Zhang Y, et al. Conserved intronic secondary structures with concealed branch sites regulate alternative splicing of poison exons. Nucleic Acids Res. 2024;52:6002\u201316.","journal-title":"Nucleic Acids Res"},{"key":"8964_CR54","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/modpathol.2014.146","volume":"28","author":"Y Gokmen-Polar","year":"2015","unstructured":"Gokmen-Polar Y, Neelamraju Y, Goswami CP, Gu X, Nallamothu G, Janga SC, et al. Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. Mod Pathol. 2015;28:677\u201385.","journal-title":"Mod Pathol"},{"key":"8964_CR55","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-16-2020","volume":"23","author":"K Chen","year":"2017","unstructured":"Chen K, Xiao H, Zeng J, Yu G, Zhou H, Huang C, et al. Alternative splicing of EZH2 pre-mRNA by SF3B3 contributes to the tumorigenic potential of renal cancer. Clin Cancer Res. 2017;23:3428\u201341.","journal-title":"Clin Cancer Res"},{"key":"8964_CR56","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrg3778","volume":"15","author":"XD Fu","year":"2014","unstructured":"Fu XD, Ares M Jr. Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet. 2014;15:689\u2013701.","journal-title":"Nat Rev Genet"},{"key":"8964_CR57","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1002\/1873-3468.13119","volume":"592","author":"H Dvinge","year":"2018","unstructured":"Dvinge H. Regulation of alternative mRNA splicing: old players and new perspectives. FEBS Lett. 2018;592:2987\u20133006.","journal-title":"FEBS Lett"},{"key":"8964_CR58","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s12253-019-00745-7","volume":"26","author":"PJ Spachmann","year":"2020","unstructured":"Spachmann PJ, Azzolina V, Weber F, Evert M, Eckstein M, Denzinger S, et al. Loss of CHEK2 predicts progression in stage pT1 non-muscle-invasive bladder cancer (NMIBC). Pathol Oncol Res. 2020;26:1625\u201332.","journal-title":"Pathol Oncol Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08964-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08964-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08964-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:17:55Z","timestamp":1786663075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08964-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8964"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08964-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All procedures involving human were approved by the Ethics Committees of Sun Yat-sen Memorial Hospital, Sun Yat-sen University (approval no. SYSKY-2023-076-01). Informed consent was obtained from each patient. The procedures for the animal experiments were evaluated and approved by the Animal Ethical and Welfare Committee of the Sixth Affiliated Hospital of Sun Yat-sen University (approval no. SYSU-IACUC-2025-060801) in compliance with the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"726"}}